Skip to content
10-Q

Quarterly Report

Telomir Pharmaceuticals, Inc. TELO

0001493152-26-023010

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 68.77M sh
Shares Diluted Q1 2026 · Mar 31, 2026 34.38M sh
Shares Diluted Q1 2026 · Mar 31, 2025 29.76M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.77M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$863.13K
Stockholders Equity Q1 2026 · Mar 31, 2026 $4.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.91M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$161.11K
Stockholders Equity Q1 2026 · Dec 31, 2024 $643.04K
Current Liabilities Q1 2026 · Mar 31, 2026 $827.31K
Current Liabilities Q1 2026 · Dec 31, 2025 $1.43M
Total Liabilities Q1 2026 · Mar 31, 2026 $827.31K
Total Liabilities Q1 2026 · Dec 31, 2025 $1.43M
Current Assets Q1 2026 · Mar 31, 2026 $5.79M
Current Assets Q1 2026 · Dec 31, 2025 $7.34M
Total Assets Q1 2026 · Mar 31, 2026 $5.79M
Total Assets Q1 2026 · Dec 31, 2025 $7.34M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.07
Eps Basic Q1 2026 · Mar 31, 2026 −$0.03
Eps Basic Q1 2026 · Mar 31, 2025 −$0.07
Sga Expense Q1 2026 · Mar 31, 2026 $573.54K
Sga Expense Q1 2026 · Mar 31, 2025 $1.85M
Rd Expense Q1 2026 · Mar 31, 2026 $467.8K
Rd Expense Q1 2026 · Mar 31, 2025 $337K
Net Income Q1 2026 · Mar 31, 2026 −$990.95K
Net Income Q1 2026 · Mar 31, 2025 −$2.18M